Clinical Trial

Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Name: Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma — clinical trial record (NCT07460245)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AVESEC

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Record status

This record was last updated March 10, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Summary

This study represents an innovative opportunity in the treatment of metastatic urothelial carcinoma

Trial Details

NCT Number	NCT07460245
Lead Sponsor	Gruppo Oncologico Italiano di Ricerca Clinica
Conditions	Urothelial Carcinoma
Enrollment	144 participants
Start Date	2026-06
Primary Completion	2026-06 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-10